Praetego
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company does
Praetego is a Durham, North Carolina-based pharmaceutical company founded in 2017, developing treatments for neurodegenerative diseases. Its lead candidate PTG-630 is an oral small molecule targeting oxidative stress and glucotoxicity - key contributors to neurodegeneration. It has raised about $6.1 million and holds granted patents on inhibitors of advanced glycation end products; CB Insights lists it as Alive.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Praetego founded in Durham, North Carolina to develop neuroprotective drug candidates.
- Patent granted
A key patent on inhibitors of advanced glycation end products (diabetes/kidney disease applications) was granted in November 2024.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.